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Colorectal cancer is the second deadliest cancer in the US due to mortality from eventual 
metastatic outgrowth. The National Cancer Institute estimates that approximately 136,000 men 
and women will be diagnosed with colorectal cancer in 2014 alone, with greater than a third 
dying from the disease during the same period. While primary tumors can be effectively treated 
with surgical resection if diagnosed prior to spreading from the primary site, the 5-year survival 
rate for cases with distant metastasis is a dismal 13% despite current therapeutic intervention, 
highlighting the unmet need for a more efficacious approach.  
Targeted cancer therapy holds much promise but few standout successes because the markers are 
broadly expressed in both healthy and diseased tissue. The transmembrane protein guanylyl 
cyclase C (GCC), however, provides the specificity for targeted therapy: it is selectively 
expressed in intestinal epithelium; absent in healthy extra-intestinal tissues; and expressed 
through the metastatic event. Here we investigated signal amplification via an avidin biotin 
complex (ABC) with an ST-biotin pretargeting moiety, a GCC exogenous ligand labeled with 
biotin, complexed with tetrameric avidin and tertiary detection with
125
I -labeled biotin. We 
demonstrated that while the ST-biotin delivery of avidin-
125
I-biotin to GCC fails, biotin-IgG is a 
tenable system in vitro, but with significantly diminished amplification in vivo.  
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Simultaneously we demonstrated that the GCC monoclonal antibody (GCCmAb) generated for 
diagnostic pretargeting internalized in the acidic, reductive environment of the lysosomal 
compartment. Ricin, a two-part toxin derived from the castor oil plant Ricinus communis, which 
depurinates the ribosome halting protein synthesis, also travels through the endosomal-lysosomal 
pathway causing cytotoxicity. Leveraging these shared characteristics to provide the proof of 
concept for GCC-dependent intracellular payload delivery, we generated an immunotoxin (IT) 
linking the GCCmAb targeting moiety via a disulfide bond to the catalytic A chain of ricin toxin 
(RTA). Targeting GCC provides cellular specificity, while disulfide linkage endows subcellular 
release of RTA to act on the ribosome and inhibit protein synthesis. GCC-IT therapy reduces 
tumor burden in vivo fivefold versus controls, providing proof of concept for subcellular 
deliverable GCC therapeutics targeting colorectal cancer metastasis. 
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 CHAPTER 1: INTRODUCTION  
Colorectal cancer is the third most prevalent and lethal form of cancer in the United States 
according to 2014 estimates from the National Cancer Institute. Only cancer of the lungs and the 
male and female related cancers, prostate and breast respectively, have a higher incidence and 
mortality rate (Fig. 1). 
 
 
 
Figure 1. 2014 Cancer Statistics (1) 
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While the disease is highly treatable through surgical resection and offers an average 90% 5-year 
survival rate for patients with disease localized to the primary site, presence of disease at regional 
sites at the time of diagnosis reduces the 5-year survival to 70%, while distant metastasis 
precipitously drops survival to 13% across all races (Fig.2). Provided that the patient receives 
early diagnosis via regular colonoscopies and subsequent screening for metastatic disease, there is 
a great likelihood that they will survive. However, as colorectal cancer patients do not die from 
the cancer at the primary site, it is clear that there is a disparity in standard of care which relegates 
the more progressed patients to die from their metastatic disease. This reveals the need for both 
earlier diagnosis and treatment of metastatic disease patients (1). 
 
 
 
Figure 2. 5-year survival rate by race and stage at diagnosis. 5-year survival rates of 
colorectal cancer patients by race and stage of disease at time of diagnosis in the United States 
from 2003-2009 (1) 
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Early detection of primary disease by colonoscopy, while the tumor remains local to the site of 
origin, allows for the best 5-year survival rate of 90%. The diagnosis of distant metastasis and 
subsequent gauging of their response to therapy is currently dependent upon fluorodeoxyglucose 
(FDG) with positron emission tomography (PET) imaging, and blood screening for tumor related  
markers (2). FDG is preferentially taken up by cancer tissue as they are more metabolically active 
and consume a disproportionate amount of sugar relative to healthy tissue. This increased uptake 
leads to higher levels of the radioactive glucose in the tumor and nodal signal detection by PET 
imaging.  Blood tests may also be used to stage and monitor patients. Increased levels of 
carcinoembryonic antigen (CEA) (3), carbohydrate antigen (CA) 19-9(4), liver enzymes (5), or 
complete blood count can signify a progression of the disease (6). These measures are limited in 
that they only leverage a relative increase in markers related to cancerous tissue. FDG is also 
taken up by healthy, highly metabolic tissue such as the brain, thereby obfuscating any resolution 
of detection with a high background signal. Blood screens for circulating markers often generate 
false positives or false negatives as they can be decreased in disease patients or increased in 
healthy individuals, as is the case with CEA in patients who smoke or have chronic lung disease 
(7). These markers are only useful if biopsies confirm that the tumor is in fact the source, and the 
levels rise and fall with disease progression and treatment.  
Current standard of care for distant tumors falls short due to the lack of specificity of treatments 
as well. Possible regimens for treatment include the thymidylate synthase inhibitor 5-fluorouracil 
(5-FU) which halts DNA replication via blockage of thymidine synthesis (8). 5-FU may be 
coupled with adjuvants folinic acid (leucovorin) which furthers 5-FU effects by inhibiting 
thymidylate synthase and oxaliplatin, a platinum based compound which crosslinks DNA(9, 10). 
This combination therapeutic schedule is called FOLFOX (11). 5-FU may also be combined with 
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leucovorin and irinotecan, a topoisomerase inhibitor, for a dosing regimen termed FOLFIRI (12). 
Irinotecan or oxaliplatin may each be used as a stand-alone treatment or individually combined 
with Capecitabine, a pro-drug which is metabolized to become 5-FU (13). Common to all of these 
chemotherapies is their target, DNA, and their leveraging of the increased division rate of cancer 
cells for their mechanism of action, effecting DNA replication and division and therefore tumor 
growth. The increased turnover rate of cancer cells results in uneven uptake of the chemotherapy 
in the tumor compared to healthy tissue, and as most adult tissue is not rapidly dividing in 
comparison, a reduction in tumor burden can be seen.  However, this is too broad a strategy to 
treating cancer, as it impacts other actively dividing tissue such as hair and gastrointestinal cells, 
resulting in the classical alopecia and nausea experienced by chemotherapy patients, creating 
dose-limiting toxicities (14).   
A more specific strategy would be to target cancer cells by the proteins they express differentially 
from other tissues. Cetuximab, a monoclonal antibody (mAb) whose binding inhibits epidermal 
growth factor receptor (EGFR) and thereby inhibits cell proliferation, utilizes such an approach as 
it predominantly affects cells with increased EGFR expression (15, 16). Yet again, colorectal 
cancer metastasis are not the only extra-intestinal tissue which have this targeted phenotype as 
lung, skin, pancreas, uterus, cervix, bladder, and prostate all express EGFR, albeit at lower levels 
(17-19). So although more targeted, cetuximab still can have an adverse effect on healthy tissue, 
relying on the overexpression of EGFR, similar to the leveraging of the hyper-proliferative 
phenotype and 5-FU. In addition, cetuximab is not useful in colorectal cancers whose 
proliferation is due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (20). As 
EGFR sits upstream of KRAS in the growth factor signaling pathway, a mutation to KRAS which 
results in constitutively active growth factor signaling leaves only cells expressing wild type 
KRAS susceptible to cetuximab therapy, further limiting the possible therapeutic efficacy.  
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Bevacizumab, another monoclonal antibody, also provides some degree of specificity in 
treatment by targeting vascular endothelial growth factor (VEGF) (21). Tumors require support 
from blood supply, as all tissues do, in order to grow. This remodeling of the tumor 
microenvironment to provide new vascular tissue is termed angiogenesis. As bevacizumab blocks 
the VEGF receptor, similar to cetuximab and EGFR, it inhibits angiogenesis and effectively 
starves the tumor of newly formed vasculature. Again, VEGF receptors are not restricted in 
expression to the site of the tumor, and are found playing a neuroprotective role in the 
hippocampus by maintaining non-hypoxic conditions and glucose supply, as well as similar 
functions in all endothelial cells (22). Not surprisingly blocking VEGF also can result in 
myocardial infarction. Finally, ziv-aflibercept, a competitive receptor for VEGF also inhibits 
angiogenesis by sequestering the ligands which activate the VEGF receptor, rather than blocking 
the receptor as bevacizumab does (23). Ziv-ablibercept also shares the adverse effects typical of 
cancer therapies such as diarrhea, fatigue, and nausea, but also introduces hypertension and risk 
of conjunctival hemorrhage to the list (24). With all of these therapies there is implicit collateral 
damage that has to be managed throughout therapy, often limiting dose schedules. The need for a 
truly specific tumor target, one that isn’t a common requirement of all cells and only up-regulated 
in cancer, is still very apparent. 
Guanylyl Cyclase-C (GCC), a transmembrane receptor on the apical membrane of intestinal 
epithelium that regulates salt and water transport, has been demonstrated as an effective specific 
biomarker for metastatic colon cancer (25). As a biomarker, the most important property of GCC 
is its persistent expression throughout the tumor formation and metastatic processes. Confirmed 
by PCR and Northern blot analysis (Fig. 3) and 
125
I-ST membrane binding (Fig. 4), GCC 
expression is present in both primary and metastasized colorectal adenocarcinomas but absent in 
normal extraintestinal tissues (26).  Sequestration of access to GCC protein on the luminal 
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membrane by epithelial tight junctions is significantly fortuitous in that an impermeable 
histological barrier is created between the intestine and vascular compartment (27-32). Even 
through immunological assault, neither autoimmunity nor exacerbation of chemically induced 
inflammatory bowel disease manifests. Intravenous administration of GCC-viral vectors against 
pulmonary colon metastasis reveals that targeting of extraintestinal tissue is possible without 
accessing the normal GCC expressing intestinal tissue as no chronic inflammation due to 
autoimmunity resulted (33).  GCC has been specifically targeted in metastatic adenocarcinomas 
with differential uptake through conjugation of a radionuclide to the 18 amino acid peptide 
produced by Escherichia coli, heat stable enterotoxin ST which binds specifically to GCC. Wolfe, 
et al. conjugated 99mTc to ST (
99
TC-NC100586) in such a manner that binding capacities were 
not significantly altered and gamma imaging definitively showed the capacity of GCC to act as a 
specific marker for non-invasive metastatic detection (Fig.5A-B) (34). Therefore, as opposed to 
the current standard of care, GCC should provide the specificity for truly targeted diagnosis and 
therapy.  
 
 
 
Figure 3. Detection of GCC by RT-PCR. Northern blots of RT-PCR performed using mRNA 
purified from indicated tissues using primers for GCC (top) with control β-actin (bottom) (26). 
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Figure 4. Radiolabeled ligand binding to membrane preparations of various tissues. 
(adapted from Carrithers, et. al. 1996 (34)) Membrane preparations of tissues from healthy 
intestinal tissue, healthy exraintestinal tissue and colorectal cancer samples from liver, lung, 
lymph node, ovaries, and peritoneal tissues bound with 
125
I-ST. 
 
 
 
0
10
20
30
40
50
60
70
Fm
o
l S
T 
b
o
u
n
d
 /
 m
g 
p
ro
te
in
 
Ligand Binding 
8 
 
 
Figure 5. Imaging of subcutaneous T84 tumors in nude mice. (A) 
99
TC-NC100586 was 
injected via tail vein into nude mice xenografted with subcutaneous T84 tumors in the absence 
(left) or presence of 50ug (center) or 100ug (right) of unlabeled STa  120min prior to gamma 
camera imaging. (B) Targeting of T84 live metastasis model imaged 120min after 
99
TC-
NC100586 injection and immediately after harvesting liver imaged by gamma camera 
scintigraphy.  
 
 
 
While the preliminary data demonstrated by Wolfe, et al. was promising, there were still 
theoretical improvements that could have been made to improve the diagnostic value of GCC 
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targeted imaging. When ST is directly conjugated to its reporter molecule, 
125
I or 
99m
TC it is only 
capable of delivering a single reporter payload at a time. Delivery agents capable of signal 
amplification, i.e. carrying more than one effector molecule or payload per agent, can further 
improve the efficiency of targeted biomarkers. In imaging, multiple effector molecules increase 
signal-to-noise ratio and enhance image contrast. For therapeutic applications such as 
radiotherapy, increased radiation dosage to targeted tumor cells improves efficacy.  The avidin 
biotin complex, ABC, can potentially be used to provide multiple-payload delivery in vivo as it 
has been widely used in laboratory assays such as ELISA and IHC to amplify and bridge 
targeting agents and detection payloads (35). Avidin, the 66kD tetrameric protein derived from 
chicken egg white, provides amplification by binding to up to 4 Biotin (i.e. Vitamin H) per 
molecule. In addition, the dissociation constant between Avidin and Biotin, at Kd=10
-15
M, is one 
of the strongest non-covalent bonds (36). Therefore a single effector molecule can be used 
through the ABC to deliver three payload molecules even at very low concentrations. 
Biotinylation, the linking of biotin to proteins, of both a targeting molecule and a payload 
molecule, allows for ABC construction of a macromolecule of your choosing without 
jeopardizing the binding activity of the respective biotinylated molecule (37). Biotinylation, 
although also possible through glycoconjugates, biotin maleimides, or photoreactive biotin 
compounds, is commonly achieved through N-HydroxySuccinimide-biotin (NHS-biotin), and is 
the preferred method as it readily binds to the amine termini of lysine residues which are usually 
prevalent and in exposed positions in proteins (38). Averaging 90-350 amine sites per IgG 
molecule,  poly-biotinylation of antibodies is not only possible, but common, depending on molar 
ratio of NHS-biotin to antibody during conjugation (39). Consequently, multiple biotins are 
available for avidin to bind per antibody in addition to the amplification by avidin’s tetrameric 
characteristic. Rather than requiring high specific activity by directly labeling the targeting agent, 
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a robust signal by means of amplification at both the poly-biotinylation step and payload ABC 
step is possible.  
 The macromolecule targeting strategy we investigated is begins with a targeting moiety, 
biotinylated ST or biotinylated mAb to GCC. Secondary labeling with avidin as an amplifier and 
a bridge provides the binding sites for radiolabeled biotinylated peptides. This complete targeting 
agent can be built from stoichiometric mixtures of the biotinylated targeting agent (antibody), 
avidin, and biotinylated payload molecule and subsequent filtering for size exclusion for one 
purified complex. This however is not optimal for in vivo delivery. Rather, the complex can be 
created in situ through pretargeting, a technique used to dose the patient with each component of 
the full complex in sequence, allowing clearance of unbound targeting moiety or avidin to clear 
prior to chasing with the biotinylated reporter. Pretargeting builds the molecule in-situ, piece by 
piece. This is possible due to the long bioavailability of antibodies or conversely quick binding 
and clearance of ST, and the quick clearance of avidin by the liver. Typical pretargeting involves 
initial administration of  targeting moiety, waiting a short time for binding and clearance, a 
secondary clearance and bridging step via an avidin chase in order to remove endogenous biotin 
and further build the complex with the antibody, and then within hours the administration of the 
radiolabeled biotin (Fig. 6). Pretargeting with a system that provides no amplification via 
stoichiometry inherent in the complex has shown to increase tumor to background ratios by 
nearly 6 fold over directly labeled targeting agents by lowering nonspecific binding (40). Not 
only does the ABC system allow for a more robust signal through stoichiometric amplification, 
but it is further elevated by construction through pretargeting. It was hypothesized that our 
detection technique which combines a high signal through amplification, low noise through 
pretargeting, and high specificity via the biomarker GCC could have proved the most sensitive to 
date.   
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Figure 6. Principles of pretargeting. Principle theory and protocol of pretargeting for delivery 
of a payload. GCC expressing metastasis in extraintestinal tissue (top left) are available for 
binding by a targeting moiety of either biotinylated ligand or biotinylated mAb (top right). After a 
washout period, a bridging tetrameric avidin secondary label is administered (bottom right). 
Finally, tertiary labeling is accomplished through administration of biotinylated payload which 
can deliver therapy or diagnostic agents (bottom left) such as radiation in this illustration. 
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CHAPTER 2: PRETARGETING WITH EXOGENOUS LIGAND 
As the targeting moiety of ST has the most favorable in vivo clearance characteristics, binding to 
GCC and excess renal clearance within 2 hour period, its performance in ABC delivery was first 
investigated. Since ST would bind our complex to cells, we had TJU synthesized. TJU is a 
peptide identical to ST (ST amino acid sequence: NTFYCCELCCNPACAGCY) in sequence save 
the cysteines having been replaced with alanines (TJU amino acid sequence: 
NTFYAAELAANPAAAGAY) and therefore lacking in the three disulfide bonds requisite for 
tertiarty structure and GCC binding. This was chosen as biotinylation, iodination, and purification 
were already known for ST, so
125
I-TJU-biotin preparation would simply parallel that of ST-
biotin. TJU-biotin could act as a negative control in the first step of pretargeting, and 
125
I-TJU-
biotion would serve as the delivery payload in all systems. Much time was spent attempting 
variable stoichiometric ratios with a pre-built complex of ST-biotin, Avidin, and 
125
I-TJU-biotin 
prior to exposure to fixed cells both with and without GCC expression, all with no success. In 
attempting to figure out possible confounding issues in our procedure, we revisited our 
purification approach used post iodination. It was assumed that the C-18 sepak columns were able 
to separate the unbound 556.59 kDa sulfo-NHS-LC-biotin from successfully linked ST-biotin at a 
combined final size of approximately 2300 kDa, 1972 kDa for ST and 339.5 kDa for reacted 
linkage size. Procedurally, we first biotinylated ST and TJU, then iodinated each of them, and 
finally, theoretically desalted both free iodine and free biotin simultaneously. In order to test this 
theoretical purification, we applied the same C-18 sep-pak purification protocol (see methods and 
materials) to a sample of biotin-4-fluorescein which could then be detected at excitation and 
emission of 494nm and 521nm respectively.  
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Figure 7. Purification profile of 
125
I-ST-biotin. Fractionated washing of 
125
I-ST post iodination 
with increasing concentrations of acetonitrile in 10mM sodium acetate. Iodination reaction is 
added to the column followed by 13 washes of sodium acetate (1-13), 10 washes of 20% 
acetonitrile (14-23), 10 washes of 30% acetonitrile (24-33), washes of 40% acetonitrile (34-43), 
and finally washes of 70% acetonitrile (44-53). Peaks counts at 15, 16, and 17 were collected.  
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Figure 8. Purification profile of biotin-4-fluoroscein. Following the same protocol as 
125
I-ST 
purification, biotin-4-fluoroscein fractionated washes with increasing concentrations of 
acetonitrile in 10mM sodium acetate. Biotin-4-fluoroscein is added to the column, followed by 13 
washes of sodium acetate (1-13), 10 washes of 20% acetonitrile (14-23), 10 washes of 30% 
acetonitrile (24-33), washes of 40% acetonitrile (34-43), and finally washes of 70% acetonitrile 
(44-53).  
 
 
 
It had previously been assumed that unbound biotin would be removed concomitantly with 
unbound 
125
I when purifying post ligand iodination. However, the fractionation profile of 
desalting 
125
I-ST (Fig. 7) is identical to that of biotin-4-fluorescein (Fig. 8). So when we collected 
the peaks of 
125
I-ST-biotin, we were not collecting a pure fraction, we were also recovering free 
biotin. This means that we were including a competitive ligand for avidin in our incubations, and 
possibly confounding our stoichiometric calculations and reactions.  
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In order to overcome this contaminating free biotin issue, we ordered TJU synthesized with biotin 
already bound the amine terminus (Fig. 9). Since the cost of ST synthesis was expensive enough 
on its own, we still had to biotinylate our stock of ST in house, and then use HPLC in order to 
purify the fraction containing only ST-biotin, as our C-18 sep-pak column purification did not 
have the resolution required.  
 
 
 
Figure 9. Mass spectrometry of HPLC purification of TJU-biotin. Purification of synthesized 
HPLC  TJU-biotin by ChemPep, Inc. yielding 95.36% purity and delivered as a 6.0 mg of 
lyophilized white powder. The largest molecular weight peptide peak was collected (red oval).  
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Figure 10. Mass spectrometry of HPLC purification of ST-biotin. Thomas Jefferson 
University proteomics core HPLC purified ST-biotin reaction with TJU-biotin synthesis protocol 
from ChemPep, Inc. The largest molecular weight peak peptide was collected.   
 
 
Fortuitously, ChemPep, Inc. provided us with their purification protocol which was then 
communicated to the Thomas Jefferson University proteomics core for purification of ST-biotin 
(Fig. 10). As there were only two majority peaks accounting for the smaller free biotin driving the 
reaction and the larger single species ST-biotin, we now had confidence that we had a pure 
population of ST-biotin, free of unbound biotin and unlabeled ST.  
In order to confirm our pieces of our complex functioned as intended we then iodinated 10ug 
each of ST-biotin and TJU-biotin.  Applying 
125
I-ST-biotin to intestinal membrane preparations in 
direct comparison to 
125
I-ST we can see that biotinylation of ST did not affect its binding 
characteristics to GCC (Figure 11). Additionally, we confirmed that the avidin binding 
functionality conferred to each ligand via biotinylation was not destroyed via iodination and 
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subsequent purification. Utilizing avidin bound to agarose beads we were able to apply our 
ligands, allow for binding, and wash away unbound peptides with centrifugation to pellet the 
avidin bound to the agarose (Fig.12)  
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Figure 11. 
125
I-ST vs 
125
I-ST-biotin intestinal membrane binding. Intestinal membrane  
preparations were blocked with binding buffer for 1h at 37°C prior to incubation with a titration 
of   
125
I-ST-biotin (left) or 
125
I-ST (right) for 1h at 37°C. Membranes were then washed three 
times with binding buffer and quantified in a gamma counter. 
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Figure 12. Avidin binding capacity of biotinylated peptides. Binding of increasing 
concentrations of 
125
I-ST-biotin and 
125
I-TJU-biotin to avidin agarose beads over a 3 hour period. 
Beads were washed three times with binding buffer prior to quantification by gamma counter.  
 
 
With ST-biotin and 
125
I-TJU-biotin confidently pure and functional in hand, we returned to the in 
vitro fixed cell assay that had yielded nothing for us before. In order to take logical steps forward 
in the build process rather than jump directly to a three step build, we asked if ST-biotin could 
tether even an iodinated avidin molecule to GCC (Fig. 13). Compared to fixed GCC expressing 
cells completely pre-blocked with unlabeled ST, cells which sequentially saw ST-biotin for 1 
hour at 37
°
C, washed three times, and then exposed to 
125
I-avidin for an additional 1 hour at 37
°
C 
prior to washing, solubilization, and counting resulted in no differential of signal while cells who 
were simply exposed to 
125
I-ST returned significantly increased signal relative to unlabeled ST 
blocked cells.  
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Figure 13. Radioactive signal delivery to GCC via ST-biotin 
125
I-Avidin or 
125
I-ST. Methanol 
fixed and permeabilized GCC expressing cells were pre-exposed nothing or unlabeled ST prior to 
ST-biotin, washing and then exposure to 
125
I-Avidin, washed and quantified. Simultaneously, 
cells with and without unlabeled ST pretreatment were exposed to 
125
I-ST, washed and quantified.  
 
 
This inability to return any secondary label to GCC highlighted the need for a positive 
experimental control. Our engineered cell lines were comprised of CT26 cells, normally devoid 
of GCC, stably transfected with the extracellular domain of GCC with just the transmembrane 
region on the C termini to retain the protein on the surface of the cell. This construct was used 
previously to insure the targeting of GCC was not affected by any downstream activity of the 
cyclase. The GCCtm sequence also cells had a hexa-histidine repeat (HIS tag) at its c-terminal 
tail, serving as a positive control for transfection. If the His tag could be detected via western blot, 
compared to parental CT26 cells, then there was evidence that the cells expressing the His tag 
were also expressing the GCC protein. Using an off the shelf biotinylated antibody targeting that 
c-terminal HIS on the GCC, we had a system which would give us some indication if our 
pretargeting system was even remotely close to functioning. Compared to ST-biotin, biotinylated 
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monoclonal antibody against the His tag was able to return a positive signal on methanol fixed 
CT26.GCCtm cells via the fluorescent avidin reporter, avidin R phycoerythrin (R-PE), and 
returned no signal on CT26 cells or CT26.GCCtm cells when exposed to avidin R-PE alone 
(fig.14).  
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Figure 14.  ST-biotin pretargting vs Anti-His-biotin pretargeting.  (A) Fluorescent images are 
gained to CT26 cells within treatment groups CT26 (left) and CT26.GCC (right) cells were 
exposed to ST-biotin or anti-His-Ab-biotin for 1 hour, washed, and exposed to avidin-R-PE for 
one hour prior to washing and imaging. Exposure of CT26.GCC cells just to avidin-R-PE 
demonstrate degree of avidin-R-PE non-specific binding (center). (B) Fluorescence quantified 
with ImageJ. Bar charts are quantification of fluorescent intensity of avidin-R-PE alone versus 
pretargeting.  
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With this data against ST-biotin delivery, we had enough evidence to suggest we should move 
forward with generating true antibodies against GCC so as to create a library of possible targeting 
moieties that were able to deliver a payload larger than
125
I to GCC.  
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CHAPTER 3: PRETARGETING WITH MONOCLONAL ANTIBODY 
GCC monoclonal antibodies were generated against the extracellular domain as detailed in 
methods and materials. Briefly, GCC-/- mice were immunized with Adenovirus GCC, 
subsequently boosted with CT26.GCCtm twice, and two final times with purified GCC 
extracellular domain protein for a total of four immunization boosts. Spleens were harvested and 
fused to immortalize the cells prior to limiting dilutions to assure clonal populations. Twenty four 
clones survived with specific mouse GCC (mGCC) antibody recognition as measured by ELISA 
(Fig. 15).  Surviving clones were also tested for recognition of human GCC (hGCC). Those 
which demonstrated high signals and or had recognition of both mouse GCC (mGCC) and hGCC 
were moved to hybridoma factories for antibody production and purification.  
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Figure 15. Antibody ELISA screening. Media samples from hybridomas were exposed to 
ELISA plates coated with mGCC, hGCC, and irrelevant protein GST. Plates were washed and 
probed with anti-mouse HRP, developed with TMB for colorimetric quantification.    
 
 
As antibodies were produced and purified via protein G columns, they were then biotinylated. As 
opposed to ST which only had a single amine terminus, IgG molecules contain hundreds of 
possible amine termini which would react with the sulfo-NHS-biotin. Although this was 
favorable in the sense that you could now deliver multiple avidin molecules per targeting moiety, 
it also introduced a risk that hadn’t existed with ST, over-biotinylation. The ST biotinylation 
reaction was able to be driven to complete labeling because the single amine termini biotin did 
not interfere with the binding of ST as demonstrated previously in the membrane binding assay. 
Caution must be taken when labeling antibodies via amine termini as some of them reside in or 
near binding domains, or will simply provide diminishing returns when labeling with avidin as 
steric hindrance will only allow so many molecules of avidin to be tethered to the mAb via biotin 
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while still able to bind to its target, GCC. In order to optimize the biotinylation, we varied the 
ratio of sulfo-NHS-biotin to antibody in the reaction, quenched amine reactivity with an excess of 
glycine, and purified via a 10 kDa centricon. Free biotin flowed through, and retained mAb-biotin 
was assayed for its ability to delivery avidin-HRP in a two-step pretargeting system. First GCC or 
parallel BSA coated wells would be treated with mAb-GCC-biotin for an hour at 37°C, washed 3 
times, and then exposed to avidin-HRP, washed, developed and colorimetrically quantified with 
BSA non-specific signal subtracted from parallel wells (fig.16). As hypothesized, there is an 
optimal range of biotinylation which maximally retains a specific signal. No increase in signal 
was achieved above the 10:1 ratio biotin:mAbGCC, establishing the ratio which larger quantities 
of mAbGCC-biotin were to be created.  
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Figure 16. Varying degrees of biotinylation. GCC coated ELISA plates were exposed to 
titrations of mAbGCC biotinylated at increasing ratios of biotin to mAb. Detection via anti-
mouse-HRP (top) demonstrates retained GCC recognition without biotinylation interference. 
Detection via avidin-HRP (bottom) demonstrates ideal ratio of biotin to mAb. All numbers are 
specific binding as a parallel BSA coated ELISA was subtracted from total signal. 
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With biotinylation of mAbGCC optimized, the next step was to test it in the assay in which ST-
bio had never come close to working: the three-step pretargeting. Since we had samples of 
varying biotinylated mAbGCC, we employed them in the delivery of radiolabeled TJU in the 
methanol fixed CT26.GCCtm format (Fig. 17). Aligning with our ELISA and avidin-HRP 
readout, 10:1 ratio biotinylation of mAbGCC was also the optimal ratio for delivery of our 
tertiary label, 
125
I-TJU-biotin. We now had a tenable system for three-step delivery and signal 
amplification.  
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Figure 17. Three-step pretargeting with mAbGCC. Pretargeting of CT26 or CT26.GCCtm 
with mAbGCC labeled with varying amounts of biotin as compared to just avidin alone in 
capability of retaining 
125
I-TJU-biotin. 
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In order to see how well this three-step pretargeting system could work, we sought to optimize 
the specific signal in each step of the procedure. First was the targeting moiety mAbGCC-biotin. 
A titration of mAbGCC-biotin was exposed to cells and then detected with constant 
concentrations of avidin and 
125
I-TJU-biotin sequentially (Fig. 18). Calculating the signal to noise 
ratio, dividing retained signal in CT26.GCCtm by signal retain in CT26 cells reveals that the 
optimal dose of mAbGCC is 0.4 ug/mL with a signal to noise ratio of 4.1. Beyond that, there is an 
increase in non-specific binding to CT26 cells which reduces the specificity of the system. Next, 
the avidin concentration was to be determined in much the same way. Utilizing the 0.4 ug/mL 
previously determined, varying amounts of avidin were utilized in the three-step pretargeting 
protocol (Fig. 19). Interestingly, we see a different profile of optimal signal to noise ratio than we 
did when optimizing mAbGCC-bio. This bell shaped curve rather than a sigmoidal response is 
likely do to steric hindrance. Rather than non-specific sticking of avidin to cells independent of 
mAbGCC-bio tethering, the increased avidin possibly blocks neighboring biotin binding sites on 
other avidin molecules, thereby reducing total signal retained.    
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Figure 18. Optimizing antibody concentration. Maintaining avidin and 
125
I-TJU concentrations 
constant, methanol fixed cells were pretargeted with varying concentrations of mAbGCC-biotin 
(top). Signal to noise ratio is quantified (bottom) with best inside box.  
 
 
 
CT26 CT26.GCCtm
0
2000
4000
6000
2 ug/uL
0.16 ug/uL
0.08 ug/uL
0.016 ug/uL
0.032 ug/uL
0.00064 ug/uL
C
P
M
30 
 
CT26 CT26.GCCtm
0
1000
2000
3000
4000
1.4 uM
467 nM
156 nM
52 nM
17 nM
C
P
M
  
Figure 19. Optimizing avidin concentration. Maintaining mAbGCC-biotin and 
125
I-TJU-biotin 
concentrations constant, methanol fixed cells were pretargeted with varying concentrations of 
avidin (top). Signal to noise ratio is quantified (bottom) with best inside box.  
 
 
Having optimized primary targeting with mAbGCC-biotin and secondary labeling with avidin, 
the final optimization of the pretargeting system is the tertiary deliverable, 
125
I-TJU-biotin. 
Pretargeting with, 0.4 ug/ml mAbGCC-bio, washing, bridging with 156 nM avidin, washing, and 
increasing doses of 
125
I-TJU-biotin should reveal capabilities of our dosing system (Fig. 20). 
Compared to positive control 
125
I-ST used at a saturating concentration 100 fold above Kd, the 
piecemeal built three-step system returned dramatically more signal, one that was not able to be 
saturated.  
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Figure 20. Increasing 
125
I-TJU-biotin binding to optimized mAbGCC-bio-avidin 
pretargeting complex. Utilizing previously optimized arms of the pretargeting steps, mAbGCC 
(0.4 ug/ml) and avidin (156 nM), 
125
I-TJU-biotin was exposed to prebuilt complex at increasing 
concentrations compared to 
125
I-ST in the CT26 and CT26.GCCtm fixed cell assay. 
 
 
CHAPTER 3.1:  Temporal considerations 
While manipulation of pretargeting schedule during in vitro development is a trivial matter, 
moving to a live cell model, and then in vivo, required certain timing considerations to be taken 
into account. First and foremost was availability of mAb-GCC-biotin in the circulation. The 
amount of time the targeting moiety has to access and bind the target tumor cells was established 
with ST. But with ST-biotin unable to tether avidin, our circulating half-life of mAbGCC needed 
to be established (Fig. 21).  A mouse was injected with mAbGCC-biotin and bled five times over 
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a two week period. Serums were then exposed to the GCC based ELISA system, utilizing the 
biotin label to retain avidin HRP on the plate. Relative signals allowed for calculation of the half-
life, resulting in t1/2 =5.6 days. 
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Figure 21. Half-life curve of circulating mAbGCC-biotin. Mouse injected with 10 ug 
mAbGCC-biotin was bled vial the orbital sinus on days 1, 4, 7, 9, and 14. Serum was used at 1:2 
dilution in GCC plated ELISA, and detected with avidin-HRP. All signals are relative to negative 
control BSA plated parallel samples with signal subtracted.  
 
While this degree of serum retention of our antibody would be fortuitous in a therapeutic system, 
longer circulation allows for longer exposure to the target, in a diagnostic system it would be 
preferable to bind the target and allow the remaining unbound detection system to clear, revealing 
signal only in the target region. ST had a preferably clearance profile being small enough for 
renal clearance within 2 hours. The size of antibodies precludes them from such quick removal, 
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thereby introducing a hurdle. The bridging avidin step however provides the solution.  As avidin 
is a highly glycosylated protein, it is preferentially taken up by the liver. So when we perform our 
secondary targeting step, we both label the mAbGCC-biotin on the target, and also sequester the 
unbound circulating mAbGCC to the liver via avidin clearance. In order to prove this hypothesis, 
we again injected mice via tail vein with mAbGCC-biotin, measured circulating concentrations 
via GCC based ELISA and avidin-HRP detection both before and three hours after administration 
of avidin (Fig.22). In fact we were able to clear all signal attributable to mAbGCC-biotin in the 
circulation. 
 
 
Figure 22. Avidin scavenging of circulating mAbGCC-biotin. Mice injected with 10ug 
mAbGCC-biotin via tail vein were bled immediately before and three hours after avidin injection. 
Serum was tested in a GCC based ELISA with avidin-HRP detection. All signals are have non-
specific signal from a parallel BSA plated ELISA subtracted. 
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Once cleared from the circulation, the concentration gradient for mAbGCC-biotin to target would 
no longer be in favor of binding and moving towards equilibrium, the targeting moiety would fall 
off over time. In order to get an idea of the window for secondary and tertiary delivery, we sought 
to determine how long an antibody would remain bound to cells and available for the completed 
three step detection. First to remove any cellular dynamics, methanol fixed cells were exposed to 
the first two steps of pretargeting,  mAbGCC-bio  and avidin, then washed and left in binding 
buffer for 16h, 4h, 2h, or 30 min, prior to detection with tertiary 
125
I-TJU-biotin (Fig.23). Even 
after 16h hour incubation with lack of binding gradient, mAbGCC-bio-avidin retained significant 
signal on CT26.GCCtm above CT26 cells devoid of GCC. In a fixed, static cell system, there is a 
large window of opportunity to label the avidin tethered to the mAbGCC-biotin which is itself 
bound to the target GCC protein on the cells. Applying the same procedure to a live cell system 
(Fig. 24), we drastically reduce the time in which the mAbGCC-biotin complex is available for 
decoration with 
125
I-TJU-biotin. Therefore, when moving to in vivo studies, it is imperative to 
quickly dose the final 
125
I-TJU-biotin within 30 minutes to one hour in order to retain maximal 
signal.  
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Figure 23. Fixed cell retention of pretargeting complex. Fixed CT26.GCCtm or CT26 cells 
were exposed to the first two steps in the pretargeting protocol and the washed, and left in binding 
buffer for 30 min, 2h, 4h, or 16h prior to exposure to detection moiety 
125
I-TJU-biotin.  
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Figure 24. Live cell retention of pretargeting complex. Fixed CT26.GCCtm or CT26 cells 
were exposed to the first two steps in the pretargeting protocol and the washed, and left in binding 
buffer for 30 min, 2h, 4h, or 16h prior to exposure to detection moiety 
125
I-TJU-biotin.  
 
CHAPTER 3.2:  In vivo dosing 
Optimized dosing regimen and schedule of 0.4 ug/mL final concentration in blood (8mg/kg dose) 
of mAbGCC-biotin 24 hours prior to an avidin chase of 154nM final blood concentration 
(18ug/kg dose) to allow for complete distribution, followed finally by a maximally concentrated 
dose of 1,000,000 CPM/mouse 
125
I-TJU-biotin (6 nM final concentration) was applied to mice 
bearing subcutaneous tumors both CT26 and CT26.GCCtm on the left and right flank 
respectively. In this way, the mouse could serve as control of distribution and the tumors were to 
control for payload specificity. To insure saturation of binding sites in the tertiary step, 
125
I-TJU-
biotin, the radioactively labeled peptide was diluted with non-iodinated peptide TJU-biotin 
driving saturating concentrations for a 0.1% specific activity (Fig. 25). There was however, no 
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significant specific differential between the CT26 subcutaneous tumor and the CT26.GCCtm 
subcutaneous tumor as far as percentage of injected dose per gram.  
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Figure 25. Optimized pretargeting protocol in vivo. Mice bearing palpable subcutaneous 
tumors on the left and right flank, CT26 and CT26.GCCtm cells respectively, were each treated 
with the dosing regimen optimized in vitro. mAbGCC-biotin was injected 24 hours prior to avidin 
secondary. Tertiary 
125
I-TJU was injected 3 hours after avidin and 2 hours prior to sacrifice.  
Biodistribution results of all relevant organs quantified as percentage injected dose per gram 
organ weight (%ID/g). Means are of 3 parallel replicates. 
  
In order to compare a positive control and investigate the complex piece by piece we sought to 
compare 
125
I-ST with directly labeled antibody 
125
I-mAbGCC-biotin. The hypothesis was that 
perhaps we weren’t able to gain access to the tumors as they were not vascularized enough in a 
subcutaneous setting to allow the 150 kDa IgG access. However, the positive control of 
125
I-ST 
was able to access the subcutaneous tumor space and deliver a specific signal in CT26.GCCtm 
cells as compared to CT26 cells, 3.74 %ID/g and 0.46 %ID/g respectively (Fig.26).  Testing the 
first arm of the pretargeting in the same experiment with 
125
I-mAbGCC-biotin, we also 
demonstrate that the limitation of the system is not access of macromolecules to the tumor 
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environment as a differential 2.98 %ID/g signal was retained in the CT26.GCCtm tumors 
compared to a 1.37 %ID/g signal was retained in the CT26 tumor. Another large difference in the 
distribution profile of the 
125
I-mAbGCC-biotin compared 
125
I-ST is the large signal remaining in 
the blood. In the 
125
I-ST distribution, there is little to no signal retained in the blood, which would 
offer a clearer background if utilizing an imaging isotope, as opposed to the 
125
I-mAbGCC-biotin 
biodistribution whose blood signal would overwhelm the mediocre signal in the GCC bearing 
tumor. Repeating the experiment with 
125
I-mAbGCC-biotin and adding a titration of avidin chases 
demonstrates the ability of avidin to scavenge the mAbGCC-biotin from the blood, but with 
similar retention in the CT26.GCCtm tumor versus CT26 (Fig. 27). Varying the quantity of 
avidin in the initial optimized protocol did not return signal differential approaching 
125
I-ST. Yet 
again there was little to no signal retained in the CT26.GCCtm tumors. Finally, as a last effort we 
returned to the pretargeting mAbGCC-biotin, avidin scavenge, 
125
I-TJU-biotin, in a lung 
metastasis model which could allow for increased access and clearance due to it being a highly 
vascularized site, and the same route of metastasis seeding, intravenous tail vein injection. 
Unfortunately, there was still no differential between CT26 and CT26.GCCtm tumors despite the 
possibly favorable lung metastasis location (Fig. 28). 
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Figure 26. Biodistribution of 
125
I-St and 
125
I-mAbGCC-biotin. Mice bearing palpable 
subcutaneous tumors on the left and right flank of CT26 and CT26.GCCtm cells respectively, 
treated with either 
125
I-St for 2 hours or 
125
I-mAbGCC-biotin for 24 hours and sacrificed. (A) 
Biodistribution results of all relevant organs quantified as percentage injected dose per gram 
organ weight (%ID/g). (B) %ID/g for CT26 and CT26.GCCtm subcutaneous tumors. Means are 
of 3 parallel replicates. 
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Figure 27. Biodistribution of 
125
I-mAbGCC-biotin with avidin scavenge. Mice bearing 
palpable subcutaneous tumors on the left and right flank of CT26 and CT26.GCCtm cells 
respectively, injected via tail vein with 
125
I-mAbGCC-biotin, injected with 24 hours later of 
varying doses, and then sacrificed after another three hours. (A) Biodistribution results of all 
relevant organs quantified as percentage injected dose per gram organ weight (%ID/g). (B) %ID/g 
for CT26 and CT26.GCCtm subcutaneous tumors. Means are of 3 parallel replicates. 
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Figure 28. Biodistribution lung metastasis model. Mice injected intravenously with CT26 and 
CT26.GCCtm cells two weeks prior were treated with the 
125
I-mAbGCC-biotin, held three hours, 
and then dosed with 10 ug avidin. Biodistribution results of all relevant organs quantified as 
percentage injected dose per gram organ weight (%ID/g). Means are of 3 parallel replicates. 
 
42 
 
CHAPTER 4: GCC INTERNALIZATION 
Revisiting the availability time-course of mAbGCC-biotin-avidin complex (Fig 24,25), there is 
some additional data to be gleaned. In addition to the lack of binding gradient and complexes 
falling off GCC over time in the fixed system, there is something else at play in the live cell 
system which accelerates the loss of complex and therefore final delivered signal. Simultaneous 
to the pretargeting experiments, we began to use the mAbGCC as a biochemical tool in its own 
right. 
125I
-ST is useful for quantitative assays for protein delivery and expression, but requires a 
large degree of manipulation when investigating protein location. Monoclonal antibodies have 
become a boon over the past few decades in detection and visualization of proteins. Albeit a 
simple piece of information, visualizing protein location removes abstraction from understanding 
and can at times clearly elucidate a research path forward otherwise hidden. This was exactly the 
case of mAbGCC. As pretargeting in vivo was underway we optimized staining techniques to 
visualize a CT26.GCC cell line. Here, since we were interested in the normal biological behavior 
of the protein, we utilized CT26 cells stably transfected with the complete sequence of mouse 
GCC, rather than the GCCtm used previously as merely a surface target (Fig. 29). Surprisingly, 
when probing fully permeabilized cells in both our in vitro model as well as endogenous 
expression in the mouse intestine, we found a disproportionate amount of the protein not to be on 
the surface as had been the accepted paradigm of the field, but rather predominantly in the 
intracellular space.  
43 
 
CT26 CT26.GCCA
GUCY2C +/+GUCY2C -/-B
 
Figure 29. GCCmAb specifically binds GCC protein both exogenously and endogenously. 
(A) ELISA plates coated with BSA or GCCtm were exposed to GCCmAb (5ug/mL) and detected 
with anti-mouse HRP. (B) Activation of GCC cells with mAb competition determined via 
competitive ELISA with antibody to cGMP plated and experimental samples competed with 
biotinylated cGMP. Activity . (C) Immunofluorescent staining of methanol fixed CT26 and 
CT26.GCC cells with GCCmAb (green) counter stained with dapi for nuclei (blue). (D) 
Immunofluorescent staining of GCC (green) counterstained with dapi for nuclei (blue) in 
intestinal tissue from GCC KO or WT mice. Data are mean ± SEM. All results are representative 
of three independent replicates.  
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As GCC is a required to be surface protein with its signaling activation dependent upon binding 
from extracellular ligands, we co-stained for lysosome associated membrane protein (LAMP1), 
an end stage marker of endocytosis.  In fact the large, perinuclear compartments of GCC 
colocalized with LAMP1 (Fig. 30) in the intestine; endogenous GCC is predominantly lysosomal 
in location. 
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Figure 30. GCC resides in the intracellular space. 60x and 100x magnifications of 
immunofluorescent GCC (green) staining intestinal tissue with the additional counterstain of 
lysosomes (red) and surface protein Beta-Catenin (purple) showing colocalized foci (yellow).  
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The path which leads to the lysosome was then investigated. Nascent GCC could be formed in the 
endoplasmic reticulum, matured in the golgi apparatus, and directly translocated to the lysosome 
for an unknown function, or it could be en route from the surface of the cell. As the easier 
question to answer, and with more direct translational implication we exposed live CT26.GCC 
cells to antibody for five hours, washed them three times, and then fixed them. When we probed 
with fluorescent secondary antibody, intracellular staining could only be attributed to surface 
bound antibody which had internalized to the intracellular space (Fig. 31) Not only did GCC 
internalize, but as with the mouse intestine, we see distinct marked amounts of colocalization 
with LAMP1.   
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Figure 31. GCC internalizes to the lysosome. Cells imaged after 5h exposure to GCCmAb at 
37°C in DMEM, wash with PBS and then methanol fixed and permeabilized to visualize 
internalized GCC destination with anti-mouse (green) and counterstained for lysosomes with 
Lamp1(red) with colocalized foci (yellow). 
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To provide secondary confirmation that GCC was specifically internalized, we investigated the 
two major proteins controlling internalization: caveolin and clathrin.  Both proteins serve to 
create invaginations in the membrane, internalizing extracellular components into vesicles which 
then migrate to other regions of the cell. We inhibited both caveolin, through multiple siRNAs, 
and clathrin, through multiple shRNAs, and probed cells for internalization under live conditions 
(Fig.32,33). Not surprisingly, as caveolin is classically associated with receptor-independent 
endocytosis, there was no effect on the amount of mAbGCC internalized over a five hour period 
even under significant reduction in caveolin protein.   Furthermore, as was expected with clathrin, 
the classical scaffolding protein of receptor dependent endocytosis, a significant reduction in 
clathrin resulted in a significant reduction in internalized mAbGCC over a five hour period, 
restricting GCC to the surface of the cells.  
As we had observed a significant reduction of ST-biotin-avidin from the surface of live 
CT26.GCCtm cells compared to fixed cells in our pretargeting experiments, we now 
hypothesized that the complex may have been internalizing, thereby removing access be able to 
decorate the avidin. Applying the same techniques, siRNA to caveolin and shRNA to clathrin for 
protein inhibition, CT26.GCCtm cells exposed to mAbGCC while shRNA or siRNA inhibited 
revealed the same internalization mechanism as complete GCC protein (Fig.34). Astonishingly, 
the lack of intracellular domain on GCC did not inhibit internalization as revealed by the control 
shRNA, but the clathrin inhibited cells in fact were devoid of internalized GCC. 
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Figure 32. GCC internalization is not caveolin mediated. (A) Representative single cell 
immunofluorescent images showing internalized GCCmAb detected with fluorescent anti-mouse 
antibody (green) after 5h live exposure to 5 ug/mL GCCmAb in cells transiently transfected with 
siRNA scrambled control(I) or siRNA to caveolin(II). Cells were washed with PBS and methanol 
fixed and permeabilized prior to counterstaining for caveolin (red). Intracellular space was 
manually selected for a region of interest for quantification (dotted white line). (B) Quantification 
of caveolin and (C) GCCmAb internalized using identical region of interest within cell.  
Representative single cell immunofluorescent images showing internalized. ***=p<0.0001, One-
way ANOVA. 
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Figure 33. GCC internalization is clathrin mediated. (A) Representative single cell 
immunofluorescent images showing internalized GCCmAb detected with fluorescent anti-mouse 
antibody after live exposure to 5 ug/mL GCCmAb in cells with stably transfected shRNA control 
(shCNTRL) (I) or shRNA to clathrin (shCLTC1) (II). Cells were washed with PBS and methanol 
fixed and permeabilized prior to counterstaining for clathrin (red). (B) Quantification of clathrin 
knockdown matched to (C) quantified GCCmAb internalized. Data are mean ± SEM. All results 
are representative of ten independent replicates. ***=p<0.0001, One-way ANOVA. 
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Figure 34.  GCC translocation is independent of intracellular domain. CT26 cells stably 
expressing GCCtm and either shRNA control or shRNA to Clathrin quantified with fluorescent 
anti-mouse for GCCmAb internalization after 5h exposure at 37°C, PBS wash and methanol 
fixation and permeabilization, counterstained for matched caveolin and clathrin reduction 
quantification. ***= p<0.0001, One-way ANOVA. 
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CHAPTER 5: IMMUNOTOXIN DELIVERY 
Exploring the biological dynamics of GCC revealed the cause of difficulty for a pretargeting 
system. While the rapid internalization is unfavorable for a multi-stage targeting protocol, it is 
positively perfect for intracellular delivery. As the preliminary data demonstrated, internalized 
GCC localizes in the acidic, reductive environment of the lysosomal compartment. Ricin, a two-
part toxin derived from the castor oil plant Ricinus communis which depurinates the ribosome to 
halt protein synthesis, also travels through the endosomal-lysosomal pathway causing 
cytotoxicity (41). Ricin toxin contains two chains, B and A, which act as the binding and 
enzymatic domains, respectively. Ricin Toxin B (RTB) is a lectin which binds to galactose 
residues on the surface of cells and is linked to Ricin Toxin A (RTA) via a disulfide bond. Once 
endocytosed, the holotoxin must separate the B and A domains in the acidic environment of the 
lysosome in order for RTA to enter the cytosol and gain access to ribosomes where it acts as a 
glycosidase to inactivate the 60s subunit. This inactivation is achieved by the cleavage of the N-
glycosidic bond anchoring the purines of the ribosomal RNA from the deoxyribose. Specifically, 
the sequence 5’-AGUACGAGAGGA-3 known as the sarcin-ricin loop is depurinated to render 
the ribosome completely inactive, and therefore inhibiting protein synthesis. This depurination 
event and subsequent halting of protein synthesis theoretically requires only one molecule of 
RTA present in the cytosol in order to inactivate 1500 ribosomes per minute, far faster than the 
rate of repair. Inhibition of protein synthesis consequently leads to cell death. This highly potent 
toxin has an LD50 of only 22 ug/kg, or 1.76 mg in an average adult, by intravenous injection or 
inhalation. Oral ingestion is far less lethal requiring 1000 fold higher dose of 20-30mg/kg (42). 
Therefore we sought to leverage these shared characteristics, and provide the proof of concept for 
GCC-dependent intracellular payload delivery with an immunotoxin (IT) constructed with a GCC 
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targeting moiety, linked via disulfide bond to the catalytic A chain of ricin toxin (RTA). Off 
target effects of RTA can be further circumvented by utilizing a deglycosylated RTA (dgRTA), 
which additionally increases circulating half-life due to reduced liver uptake (43). mAbGCC 
provides cellular specificity, while disulfide linkage endows subcellular activity, as endosomal-
lysosomal reduction is required for conjugate cleavage and the cytoplasmic release of RTA to act 
on the ribosome and inhibit protein synthesis.  
Previous studies targeting GCC in vivo utilized the CT26.GCCtm as a precaution as it lacked the 
intracellular domain, and therefore would not be activated by endogenous ligand and possibly 
reduce tumor seeding. Ligand loss, and subsequent GCC signaling, is one hypothesis of why 
clinical colorectal tumors arise in the first place; loss of GCC signaling disrupts normal DNA 
damage and repair as well as control of proliferation (44). Using a cell devoid of intracellular 
signaling, CT26.GCCtm, allowed for in vivo model use without the confounding issue of 
endogenous ligand signaling. Therefore prior to generating a therapeutic that utilized mAbGCC 
against full length protein GCC, we had to confirm that normal GCC function was not affected by 
antibody binding. Cyclic guanosine-monophosphate (cGMP) is a direct downstream signal of 
GCC activation (45). By measuring for cGMP accumulation in cells with full length GCC 
exposed to antibody alone or with known activator of GCC, ST, we could determine if GCC is 
either activated by antibody or blocks activation by ST (Fig.35). mAb GCC neither blocks ST 
activation, nor activates GCC on its own and is therefore only useful as a targeting moiety for 
therapeutic means. 
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Figure 35. cGMP production is neither blocked nor activated by mAbGCC. 30 minute ST 
activation of cGMP in CT26.GCC cells with mAb competition after 30 minute IMBX 
pretreatment. cGMP levels determined via competitive EIA and normalized via BCA protein 
quantification. 
 
 CHAPTER 5.1: Immunotoxin generation. 
In order to tether the A-chain of ricin to the antibody, we would best be served to do so with a 
linker that recapitulates that of the holotoxin it came from. The B-chain of ricin is normally 
bound to the A-chain via a disulfide bond, released after entry into the reductive environment of 
the lysosome, and translocated to the cytosol. Sulfosuccinimidyl 6-[α-methyl-α-(2-pyridyldithio) 
toluamido] hexanoate (SMPT) is a linker with amine reactivity on one side and sulfhydryl 
reactivity on the other (46). Much in the same way we labeled mAbGCC with biotin, we activated 
mAbGCC with SMPT and then utilized the free sulfhydryl groups of the activated mAbGCC and 
dgRTA to recapitulate the disulfide linkage (Fig. 36). Should we link the A chain of the toxin to 
mAbGCC with a non-reducible linker  such as M-maleimidobenzoyl-N-hydoxysuccinimide ester 
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(MBS) we would theoretically reduce the potency of the toxin as it cannot escape the lysosome 
(47). MBS also reacts to the amines on  mAbGCC, but binds with the sulfhydryl group on the 
dgRTA to form a non-reducible covalent bond. Should our hypothesis of lysosomal delivery be 
wrong, the reducibility of the toxin would not affect potency, and each conjugate would perform 
with similar effects.    
 
  
 
Figure 36. Cleavable antibody immunotoxin design. Deglycosylated A chain of ricin toxin is 
linked via disulfide bond to mAbGCC.  
 
After conjugating dgRTA to GCC as described in methods and materials with MBS (ITmbs) and 
SMPT (ITsmpt),  we sought to demonstrate that our construct behaved as anticipated. As an 
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additional control we also created an isotype matched exogenous ligand IgG-smpt-dgRTA 
(ISOsmpt) immunotoxin. This construct should be identical to mAbGCC-smpt-dgRTA accept 
that it does not bind to GCC. Applying reducing conditions of beta mercapto ethanol in a western 
gel electrophoresis, or running samples without reduction, we were able to see that non-reduced 
conjugates retain ricin at a molecular weight of 180 kDa (Fig. 37). This is the anticipated size of a 
full IgG molecule and the 30 kDa dgRTA molecule. For controls we can see a light non-specific 
band at 150 kDa, in the first lane, and a 30 kDa band in the lane with just dgRTA at its non-
conjugated molecular weight. Under non reducing condition, all three ITs retain ricin at the 180 
kDa size. However, under reducing conditions, the ricin specific band falls to the 30 kDa position 
on the gel in both ITs liked with SMPT. The non-reducible conjugate, ITmbs, retains a larger size 
of dgRTA band as it is covalently liked to the 50 kDa heavy chain of IgG which results in a 
combined size of approximately 80 kDa. Additionally, to demonstrate binding capabilities of 
toxin, we exposed conjugates to irrelevant protein bovine serum albumin (BSA) or GCC plate 
coated ELISAs and detected interaction with either anti-mouseHRP (Fig 38), or sequential anti-
ricin then anti-rabbitHRP (Fig.39). The detection of the mouse IgG binding to the plate assures 
that binding of antibody is not affected by its linkage to toxin. The more valuable assay is the 
ricin detection ELISA which demonstrates that ITsmpt and ITmbs have equal delivery of dgRTA 
to the plate specifically, binding GCC and not BSA, and additionally there is no false signal from 
mAbGCC alone.   
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Figure 37. Western blot of reduced or non-reduced ITs deteting Ricin . Western blot 
detecting ricin A of immunotoxins under non-reducing (left) or reducing (right) conditions with 
GCCmAb and dgRTA as controls. 
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Figure 38. Linkage of ricin A to mAbGCC does not interfere with GCC recognition. 
GCCmAb ITmbs (non-reducible) or ITsmpt (reducible) titration of 10- 0.01 ug/mL on ELISA 
with either BSA or GCCtm coating,  anti-mouse HRP detection. 
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Figure 39. Delivery of ricin A to GCC. dgRTA, ITmbs and ITsmpt titration on ELISA with 
either BSA or GCCtm coating and anti-ricin, anti-rabbit HRP detection. 
 
CHAPTER 5.2:  In vitro cytotoxicity. 
Moving the proven conjugates to a cell system, we demonstrate efficacy of ITsmpt vs the 
negative controls of ISOsmpt or mixture of antibody and dgRTA (Fig 40). The toxicity requires 
linkage of dgRTA to antibody, and also for that antibody to be GCC specific. Furthermore, the 
reducibility of the linker is important as equal doses of ITsmpt and ITmbs do not have equal 
potency. This is now the third demonstration the GCC is internalized to a reductive compartment 
and utilization of the correct linker is vital for effective therapy. Additionally, we applied the 
effective ITsmpt to cells with shRNA to clathrin, once again demonstrating that internalization 
and, as follows under exposure to ITsmpt, toxicity is dependent upon clathrin mediated 
internalization (Fig. 41). Negative controls for shRNA remain sensitive to ITsmpt while cells 
with clathrin protein reduced are insensitive. Moreover, the same results are seen in 
CT26.GCCtm cells (Fig. 42) both in sensitivity to ITsmpt versus controls mix of mAbGCC and 
dgRTA or ISOsmpt and in insensitivity when clathrin is inhibited.  
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Figure 40. GCCmAb-IT toxicity relies on GCC expression and cleavable linkage. ITsmpt 
(reducible) toxicity vs mixture of mAb and dgRTA, ITmbs (non-reducible), or ISOsmpt (GCC 
isotype matched reducible) treated 24h after plating for 48h prior to MTT assay. The same dose 
range (0.5ug/mL-0.05ng/mL) was tested on CT26 cells lacking GCC expression. 
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Figure 41. GCCmAb-IT toxicity relies on functional clathrin. ITsmpt toxicity in stably 
transfected shCTRL cells compared to clathrin inhibition with three different shRNA constructs. 
Data are mean ± SEM. All results are representative of three independent replicates.  
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Figure 42.  GCC toxicity is independent of intracellular domain. Toxicity of ITsmpt 
(reducible) in CT26 cells stably expressing GCCtm, vs mixture of mAb and dgRTA, ITmbs(non-
reducible), or ISOsmpt (isotype matched cleavable). ITsmpt toxicity in shCTRL treated GCCtm 
cells compared to dgRTA and mAb mixture when clathrin is inhibited with three different shRNA 
constructs. Data are mean ± SEM. All results are representative of three independent replicates. 
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CHAPETR 5.3:  In vivo cytotoxicity. 
Finally to elevate the value of our effective ITsmpt, we challenged mice with a CT26.GCC lung 
metastasis model and followed with dosing regimen of ITsmpt or mixture of dgRTA and 
mAbGCC at stoichioimetrically matched ratios every 48h for a total of twelve doses. Mice were 
sacrificed two weeks after challenge, lungs harvested, and tumors enumerated (Fig.43). We found 
that mice treated with ITsmpt retained far less tumors than those treated with the mixture. 
Although the lungs were not completely devoid of tumors, as can clearly be seen from counts and 
the pictures, there is a significant reduction in tumor burden, proving this to be a viable 
therapeutic concept for targeting of metastatic colorectal cancers via GCC subcellular therapeutic 
delivery.   
 
Figure 43. GCCmAb-IT therapeutically reduces tumor burden. (A) Tumor enumeration of 
mice challenged with CT26 cells expressing GCC 1 day prior to six 0.4mg/kg doses spaced every 
other day for 12 days of mAb and dgRTA mixture or complete ITsmpt conjugate. (B) 
Representative images of lungs quantified. 
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CHAPTER 5.4: Safety. 
In order to determine safety of toxin and off-target effects, mice without lung metastasis were 
exposed to the same dosing schedule as therapeutic treatment groups, but sacrificed on the last 
day for organ harvesting and tissue histology. Control groups of vehicle, phosphate buffered 
saline (PBS), and ISOsmpt were compared to ITsmpt. Blinded histological analysis of 
hematoxylin and eosin (H&E) stained tissues including brain, lung, liver, kidney, heart, spleen, 
intestine, salivary gland, and epididymis demonstrated no significant microscopic lesions 
consistent with clinical toxicity (appendix). However, there was some evidence for potential 
early, subclinical renal effects in the two treated groups, ISOsmpt and ITsmpt. Specifically 
kidneys from mice in those groups contained occasional foci of basophilic tubules and single cell 
necrosis of cortical tubular epithelial cells with some evidence of regeneration and hypertrophy 
(Fig. 44). Although the single cell necrosis was random, scattered, individualized, and affected 
less than 1% of the renal cortex, it was slightly more severe than in the vehicle control mice and 
was thus worthy of note. Given the relatively minimal parenchymal involvement, the renal 
changes are presumed to be subclinical, although their long-term clinical significance and 
reversibility would require further investigation. Most notably was the sparing of the tissue 
endogenously expressing vast amounts of GCC, the intestine. This further confirms the 
hypothesis that GCC resides in a privileged compartment sequestered from immune system 
infiltration, and immunotoxin conjugates alike.  
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Figure 44. Potential kidney IT impact. Kidneys of mice exposed to vehicle (C), ISOsmpt (A), 
or ITsmpt (B) for 6 doses every 24 hours for 13 days. ISOsmpt and ITsmpt demonstrate the foci 
dilated and basophilic tubules largely absent from control treated mice at 40x. (D-F) Higher 
magnification (600x) of foci of basophilic tubules, single cell necrosis, and sloughing of necrotic 
cortical epithelial cells (black arrows in D&E, bent arrow in upper right hand corner inset D), and 
occasional hypertrophic tubular epithelial cells (black arrowhead in E) in mice from groups 
ISOsmpt and ITsmpt. These changes are not as prominent in the vehicle control group. 
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CHAPTER 6: DISCUSSION AND RECOMMENDATIONS 
In trying to develop a multi-stage pretargeting system, while the opportunities are present in each 
step to amplify signal delivered, there are also the inherent difficulties introduced by the same 
multitude of steps, detracting from efficacy. Even in biotinylation of the mAbGCC, there is an 
optimal degree of labeling required to maximally tether avidin, but not interfere with the antibody 
binding to its target or the avidin binding to the biotin linker. Adding to the complexity of 
concentration is timing. Not only is there a need to get the dose right, but there is also the issue of 
availability of the target over time. In retrospect, one arm of the pretargeting system which was 
not investigated as thoroughly was the possible mechanism of clearance the cellular level. 
Simultaneous to the distribution and clearance of the targeting, bridging, and payload moieties at 
the systemic level, access to the target and subsequent labeling of the target needed resolution.  
While not directly assayed with the full complex, mAbGCC tracking revealed a dynamic 
movement of GCC into the avidin inaccessible space of the lysosome.  
Beyond being a biological aside, there may also be relevant information to be gleaned from the 
observation that both GCC and GCCtm constructs internalize to the lysosome independent of 
receptor activation. This seemingly odd behavior is not unprecedented as guanylyl cyclase A 
(GC-A), the receptor for atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) has 
been shown to internalize independent of ligand binding (48). Even more pertinent may be GC-
A’s partner receptor of ANP and BNP, natriuretic peptide receptor C (NPR-C), which has a short 
intracellular domain with no known enzymatic activity and acts to bind and clear exogenous 
ligand by lysosomal degradation. Whereas GC-A has a partner for controlling ligand 
concentrations, perhaps GUCY2C plays both roles, enzymatic for cGMP production and 
simultaneously compensatory clearance mechanism of guanylin and uroguanylin. These 
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characteristics maybe requisite of all guanylyl cyclases for optimal homeostasis and both, 
activation or clearance, may be played by a single receptor or in concert with a pair of proteins. 
The revelation that the GCC predominantly resides in the lysosomal space significantly changed 
the course of research. Not only did this reveal the inherent flaw in the pretargeting approach, but 
it also revealed a leverage point for therapy. It should now go without saying, that fully 
characterizing the target protein is paramount for both diagnostic and therapeutic delivery and 
was perhaps the greatest hurdle to implementing diagnostic and therapeutic regimens.  Knowing 
that GCC rapidly internalizes to the lysosome clarifies why ST is successful as acting as a directly 
labeled conjugate for imaging, but why mAbGCC fails in a pretargeting scenario. In fact, with the 
clearance rate of ST and the speed of internalization of GCC, amplification of tumor specific 
signal may be possible via multiple repetitive doses, increasing signal with each subsequent dose 
of reporter labeled ST. This would provide the increased signal promised by long circulating half-
life directly labeled mAb, but without the burden of clearing unbound diagnostic agent.  
While mAbGCC-biotin was successful as a targeting moiety in the pretargeting system, the cause 
of ST-biotin’s failure is still unknown. Theoretically, IgG molecules exist in order to bridge and 
tether entire immune cells during interaction, while ST is merely a peptide secreted by 
opportunistic E. coli which has colonized the intestine. Hyper-activating the fluid secretion from 
intestinal cells, resulting in diarrhea, ST is merely a signal which allows E.coli to re-enter the 
environment to colonize the next host. There is no requirement for strong physical interaction, 
just signaling. To test this, we could look at binding strength with atomic force microscopy. 
Alternatively, we could determine what size payload, beyond 
125
I, ST is capable of delivering by 
increasingly PEGylating ST until unfavorable binding characteristics result. In essence, we would 
see a dose response of size versus retention of ST-PEG.  
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Therapeutically, there are other avenues that this research has opened. The ITsmpt, as effective as 
it is, does not completely clear the mice of their tumor load. Other lysosomal detonated 
therapeutics such as mayntansinoids or pH-dependent boronate-linked linear-hyperbranched 
polymeric nanovehicles may perform even better than dgRTA as payloads. Additionally, the 
targeting moiety may be improved through increasing affinity either through engineering variable 
regions accordingly, or repeated immunizations and panning for higher affinity antibody. Neither 
of these are currently high throughput methods, but should one discover such a targeting moiety, 
more payload specifically delivered to more target should improve therapeutic efficacy. Should 
one of those antibodies additionally slow the growth of the tumor merely from binding and 
activation of GCC, coupling a therapeutic payload would once again increase efficacy.  
Present use of GCC as a cancer-associated target is minimal. Snook, et al., has demonstrated that 
education of the immune system through vaccination against GCC provides decreased tumor 
burden and increased survival time (33). Importantly, a toxin-conjugate is not meant to replace 
vaccination, nor is this research intended to discount the potential use of GCC vaccination. 
Rather, each may play a vital role in the treatment of colon cancer depending on the level of 
disease progression at the time of diagnosis. Possible scenarios may play out as follows: Upon 
colonoscopy, a patient presents with resect-able primary colon polyps classified as stage 0-1. 
Further examination by probing with radiolabeled ST reveals no detectable metastasis. At this 
point, surgery is performed to remove the primary cancer, and prophylactic administration of a 
GCC vaccine is started to prevent the progression of metastatic initiation. If, however, the patient 
were to present with later stage II-III invasive carcinoma at the primary site and radio-imaging 
reveals established metastasis, toxin-conjugate administration may be the preferred initial 
treatment after surgery so as to swiftly assault the metastasis, then followed by vaccination to 
prevent recurrence. It is therefore the goal of this project to fill a void in the current treatment 
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regimen of colon cancer patients with a GCC-targeted toxin-conjugate.  In fact, the biology 
revealed in this work is now being leveraged by the pharmaceutical company Millenium 
Pharmaceuticals in clinical trials. Rather than Ricin, they have conjugated their own mAb-GCC 
via cleavable linkage to monomethyl auristatin E (MMAE), an anti-mitotic microtubule inhibitor. 
As of this writing, it has cleared the first in class phase 1 clinical trial in patients with advanced 
gastrointestinal malignancies expressing GCC as it has been well tolerated with a dose of 1.8 
mg/kg every three weeks and preliminary antitumor efficacy (49).  This movement of this 
research from my bench to patients’ bedsides further elevates the value and relevance of the work 
presented here.  
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CHAPTER 7: MATERIALS AND METHODS 
 
Biotinylation: 1 mg of Sulfo-NHS-LC Biotin was freshly resuspended in 180 uL of ultrapure 
H2O, mixed in a 20:1 molar ratio to antibody and reacted for 30 min at room temperature. Free 
biotin was remove by dialysis overnight, and degree of labeling was confirmed by HABA. Again, 
purified biotinylated antibodies were checked for viability with a GCC plated ELIZA with the 
reporter molecule being avidin HRP.  
Iodinations: 2 mCi of 
125
I, approximately 20 ul, was placed into a salt tube and vortexed gently 
for 5 minutes at room temperature to create the 
125
Iodous ion . The 
125
Iodous ion was then 
transferred to a small ependorf tube containing 10 ug of TJU-biotin peptide and gently vortexed 
for 22.5 minutes. Reaction was quenched with 1mL of 10mM NH4OAC, pH=6.8. Labeled 
peptide was then purified with C18 Sep-pak column with increasing concentrations of 
acetontitrile in 10mM sodium acetate, and fractionated peaks were tested for biotin binding 
functionality using a competitive binding assay on avidin agarose beads. 
Cell Binding: CT26 (non-GCC expressing cells) and CT26.GCCtm cells were plated in a 24 well 
dish and grown to near 90% confluency. Cells were washed twice with PBS and methanol fixed, 
then used in assays. Binding buffer consisting of 0.1% BSA, 1 mM Tris, and 3X binding buffer 
which consisted of 50 mM Tris-HCL pH=7.6, 0.66 mM Cysteamine, 0.1% Bacitracin, 450 mM 
NaCl, and 1mM EDTA, was placed in a total volume of 280 uL per well. Cells were incubated 
for 1h at 37
°
C in binding buffer prior to any ligand binding. All ligands were diluted in binding 
buffer. Cells in radioactive assays were solubilized with 1N NaOH and transferred to glass vials 
for gamma counter quantification 
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GCCmAb generation. GCC knockout mice were immunized against GCC via GCC-Adenoviral 
vaccination, followed by boosts with GCC peptide in incomplete Freund’s adjuvant (IFA) given 
intraperitoneally (IP) every two weeks until serum titers plateaued. Serum titers were analyzed 
via HIS-Tagged GCC based ELISA with a baseline immune regimen of pre-immune serum as the 
negative control and anti HIS tag antibody as the positive control. Mice with the highest serum 
titers during the plateau period were sacrificed and splenocytes were harvested. Splenocytes were 
then fused with mouse myeloma cells to generate hybridomas. Unfused cells were selected 
against in hypoxanthine-aminopterin-thymidine (HAT) medium. Surviving hybridomas then 
passed through 3 minimal rounds of limiting dilutions to assure monoclonal status. Supernatant 
from each monoclonal hybridoma was then tested for immunoreactivity in the GCC based 
ELISA. Positive clones moved on to an antibody factory for high throughput production of 
antibodies. Factory supernatants were then passed over a protein G column to purify for IgG. 
Stocks of mAb were then aliquoted at 1mg/ml and stored at-20°C with 0.01% sodium azide until 
further use.  
ELISA: Binding capacities of the monoclonal antibodies and subsequent purifications were 
screened via GCC based ELISA. Purified GCC protein was plated at room temperature overnight 
in plating buffer, washed 3x with PBS and blocked for 1 hour at room temperature with blocking 
buffer (5% milk in PBS). mAbs were then exposed to the plate for 1 hour in blocking buffer at 
varying amounts and then washed 3x with PBS. Detection of biotinylated IgG was accomplished 
with avidin-HRP. Color was developed with TMB and quenched with 1M H3P04. Wells were 
measured for absorbance at λ480nm. Binding capacities of the fully built IT conjugate as well as 
its individual components were tested via GCC based ELISA. Purified GCC protein was plated at 
room temperature overnight in plating buffer, washed 3x with PBS and blocked for 1 hour at 
room temperature with blocking buffer (5% milk in PBS). ITs were then exposed to the plate for 
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1 hour in blocking buffer at varying amounts and then washed 3x with PBS. Detection of the 
mouse IgG component was accomplished with HRP-anti-mouse H + L. Ricin A chain was 
detected with rabbit-anti-Ricin antibody and then detected with HRP-anti-rabbit H+L. Color was 
developed with TMB and quenched. Wells were measured for absorbance at λ480nm.  
cGMP accumulation. CT26.GCC cells grown to confluence in DMEM + 10% fetal bovine 
serum in a 12-well dish washed with three times with PBS, and pretreated with 500uL DMEM 
containing 1mM 3-isobutyl-1-methylxanthine (IBMX) and 10 ug/mL antibody at 37°C for 30 
minutes. Media was replaced with 500 uL fresh DMEM/IBMX/antibody mix containing 10 uM 
ST and incubated for an additional 30 minutes at 37°C prior to collection. Media concentrations 
of cyclic GMP were determined by EIA, and normalized to protein concentration of cell lysates 
of respective wells determined by BCA assay. Untransfected CT26 cells were used as a negative 
control for ST treatment, and mouse anti-NeuN (Millipore, cat #MAB377, 10ug/mL) was used as 
the control IgG. 
Immunofluorescence. Cells were plated on glass coverslips in 24 well plates at sub-confluent 
concentrations. Live cell imaging was performed in cell media buffered with 25mM HEPES. 
Cells were fixed with ice cold methanol, washed 3 times with PBS and blocked with PBS with 
5% BSA (blocking buffer). Primary antibodies exposed to cells under live conditions prior to 
fixation were detected via appropriate fluorescent secondary antibodies. Following secondary 
incubation, cells were washed 3 times with PBS and mounted to slides with dapi Pro-long anti 
fade mounting media and imaged via EVOS or confocal microscopy. Whole cell imaging assays 
were performed on CT26 mouse colorectal tumor cells engineered to express GCC, with parental 
CT26 tumor cells as controls. Slides were examined via confocal microscopy. Methanol fixed 
cells were co-stained with antibodies for cellular markers LAMP1, Clathrin and GCCmAb.  
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Internalization was manipulated via thermomechanical control. 4 °C environment halted 
movement. 37 °C released membrane rigidity. GCCmAb internalization was evaluated via 
confocal microscopy as well, live cell binding was performed with primary antibody and 
fluorescent secondary antibodies at cold conditions of 4 °C and then fixed to demonstrate only 
cell surface staining. Additional live cell binding bound primary and secondary under cold 
conditions and then allowed to warm to 37 °C for 30 minute incremental intervals prior to 
methanol fixation. Live cells were also co-stained with LAMP1 to confirm the location of 
internalized antibody.  
shRNA. GIPZ lentiviral mouse shRNA control or clathrin heavy chain constructs were acquired 
from Thermo Scientific. 1ug vsvg plasmid, 2ug delta R8.2 plasmid, and 3ug shRNA plasmid per 
12 ul FuGENE HD in a total volume of 100 ul Optimem were incubated at room temperature of 
30 minutes prior to being added drop-wise to 293T cells plated simultaneously at 3.75 x 105 
cells/mL with 4mls/10cmdish. Target cell lines were plated at sub-confluent levels in a 6 well 
plate and 293T cell media was replaced at 24 hours. At the 48 hour time point conditioned media 
from 293T cells was filtered with a 0.45uM filter and transferred to the target cells, spun for 1.5 
hours at 2700 RPM in a tabletop centrifuge and returned to 37°C incubation overnight. Fresh 
media was introduced to 293T cells for another 24 hours conditioning. At 72 hours target cells 
were again exposed to retroviral conditioned media and spun. Cells were replaced in normal 
media at 96 hours and assayed for transduction and subsequent assays 48 hours later.  
siRNA. Mouse siRNA scrambled control or caveolin were acquired from Ambion.  Cells were 
plated at low confluence in Opti-MEM. 2 uL of lipofectamine/100 uL Opti-MEM was mixed with 
100 uL containing 200 pmol of siRNA and allowed to incubate for 20 minutes at room 
temperature. The entire 200 uL reaction was then added to the freshly plated low density cells in a 
drop-wise fashion. Cells where then incubated for 24 hours, media replaced with standard culture 
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media and incubated for an additional 24 hours prior to assaying for protein inhibition and 
subsequent assays.  
Immunotoxin generation. IT conjugates were generated as previously described. Briefly, 
cleavable sulfosuccinimidyl 6-[α-methyl-α-(2-pyridyldithio) toluamido] hexanoate (SMPT) or 
non-cleavable M-maleimidobenzoyl-N-hydoxysuccinimide ester (MBS) was used to activate the 
antibody via amine reaction for 1 hour at room temperature. Simultaneously, deglycosylated 
Ricin Toxin A (dgRTA) domain (Sigma-Aldrich) was reduced with DTT to insure free sulfhydryl 
groups. Activated antibodies and reduced dgRTA were desalted on c18 columns in parallel to 
then linked to deglycosylated Ricin Toxin A (dgRTA). Activated antibodies and reduced dgRTA 
were then reacted for 72-96 hours at varying stoichiometric ratios. Final toxins were then purified 
via size exclusion and confirmed via gel electrophoresis.  
Western blots. Cells were plated days prior to probing and solubilized in LDS, reduced with 
beta-mercapto-ethanol, boiled for 10 minutes, briefly centrifuged, and loaded into 8-12% Tris-
glycine gels. Gels were run at 120V for 90 minutes, transferred via iBlot and probed for GCC 
with monoclonal antibodies. Blots were blocked for 30 minutes with 5% Milk in Tris-Buffered 
Saline with 0.01% Tween 20 (TBS-T). Blots were incubated in 5% milk TBS-T with 1ug/ml anti-
GCC for 1 hour at room temperature, washed 3 times with TBS-T, incubated for 1 hour at room 
temperature with HRP anti-mouse H+L, washed 3x with TBS-T, developed with Dura-west 
substrate, and imaged with KODAK imaging station.  
Immunotoxin toxicity assay. Cells were plated in 96 well plates to 80 percent confluence one 
day prior to experimental treatment. Cells were then exposed to a titration of IT or its respective 
non-conjugated components for 48 hours. Cells were then exposed to MTT ((3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 1 hour and then solubilized 
overnight at 37 °C. Absorbance at 590 was measured for each well and percentage of cell kill was 
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calculated in comparison to a non-treated well and a known complete kill dose of cyclohexamide. 
The following equation was used to calculate % specific toxicity:  
                    (
                                                    
                                                     
)      
Metastatic tumor model. Mice were seeded with 5 x 10
5
 GCC positive cells via tail vein 
injection 24 hours prior to therapeutic administration of IT or control non-conjugated antibody 
and toxin mixture at IT matched molarity, based on effective does of both in vitro and in vivo 
assays. Therapeutic regimen consisted of dosing mice 40 mg/kg every other day for 6 doses. Mice 
were monitored for morbidity. Mice were sacrificed on day 13, lungs injected with India ink, and 
fixed for 48 hours. Tumor enumeration was then performed under blinded conditions. 
Statistical analysis. Statistical analyses were carried out using GraphPad Prism Software v5. 
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